Leukemia, Myeloid, Acute
Conditions
Keywords
AML, phase1, MTD, Cafusertib
Brief summary
To investigate safety, tolerability of cafusertib combination with low dose cytarabine (LD-Ara-C) in Chinese patients with relapsed/refractory AML that are not eligible for conventional or intensive treatment. The dose of cafusertib will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cafusertib in combination with LD-Ara-C in AML patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of cafusertib will be observed in AML patients. To determine the recommended dosage regimen for phase II.
Interventions
Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
Sponsors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent consistent with Chinese Good Clinical Practice. * Male or female patients of age \>/= 18 years at the time of informed consent. * Patients with relapsed/refractory AML ineligible for conventional or intensive treatment. * Eastern Cooperative Oncology Group performance status score 0 - 2 at screening. * Life expectancy of at least 3 months. * Adequate hepatic, renal and metabolic function parameters: Serum total bilirubin ≤1.5 x upper limit of normal, aspartate transaminase (AST) , alanine transaminase (ALT) ≤2.5 x upper limit of normal; Creatinine clearance rate ≥60ml/min, Serum creatinine ≤1.0 x upper limit of normal; Relatively normal ECG(electrocardiogram), QTc\<450 ms(male) ,QTc\<470 ms(female); LVEF\>50%. * Patients who can comply with the trial and follow-up procedures.
Exclusion criteria
* Patients had received cafusertib hydrochloride or other PLK inhibitors. * Patients with APL. * Patients with central nervous system leukemia. * Need to continue using cytokine therapy at screening. * Patients participated in other clinical trials within 4 weeks prior to enrollment. * Patient with severe infection. * Patients with myocardial infarction had occurred within six months prior to enrollment. * Severe heart disease, including NYHA class II cardiac dysfunction and above. * Patients with HIV infection or acute and chronic viral hepatitis. * Severe gastrointestinal disorders (bleeding, infection, obstruction or greater than grade 1 diarrhea). * A previous history of neurological or psychiatric disorders, including epilepsy or dementia. * Concomitant medications with CYP3A4 inhibitors, inducers or substrates; Women pregnant or breast feeding. * Subject is thought unfit for this study by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD of cafusertib in combination with LDAraC based on the incidence of dose limiting toxicities | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy (complete remission, CR; complete remission with incomplete blood count recovery, Cri; Partial remission (PR)) | minimum 4 weeks, maximum n.a. |
| Incidence and intensity of adverse events graded according to CTCAE (version 4.0) | minimum 4 weeks, maximum n.a. |
| Incidence of dose limiting toxicity (DLT) | 4 weeks |
| Pharmacokinetics of cafusertib | 4 weeks |
Countries
China
Contacts
Primary ContactJianxiang Wang
Outcome results
None listed